Recent publications demonstrated that TRPM2 channels are highly expressed in many cancers, including melanoma (57), breast cancer (59), prostate cancer (86), tongue cancer (89), and neuroblastoma (8), suggesting that TRPM2 may promote cell survival. This evidence concerns the gene TRPM2 and prostate carcinoma.